2019

Sanofi commences tender offer for acquisition of Synthorx, Inc.

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease

Sanofi CEO unveils new strategy to drive innovation and growth

Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion

Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

Sanofi Q3 well on track

Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation

Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

Sanofi : Availability of the Pre-quarterly Results Communication

Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  

Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed

Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9

Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis

Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019

Sanofi delivered solid growth in Q2 2019

Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon

Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer

Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care

Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma

Sanofi : Availability of the Pre-quarterly Results Communication

Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union

Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate

Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma

Sanofi and Google to develop new healthcare Innovation Lab

Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments

Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer

Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma

Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission

Sanofi: Annual General Meeting of April 30, 2019

Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization

ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes

CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma

Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER

Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)

Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

Sanofi successfully prices EUR 2 billion of bond issues

Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report

Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps

Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication

Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes

Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies

Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps

Sanofi appoints Ameet Nathwani Chief Digital Officer

Sanofi delivers 2018 business EPS growth of 5.1% at CER

Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director

Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma

Sanofi : CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease

Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes

Sanofi: Availability of the Pre-quarterly Results Communication

New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs